Journal
CELL TRANSPLANTATION
Volume 22, Issue 3, Pages 423-436Publisher
SAGE PUBLICATIONS INC
DOI: 10.3727/096368912X653246
Keywords
Mesenchymal stem cells (MSCs); Migration; Insulin-like growth factor-1 (IGF-1); Acute kidney injury (AKI); Kidney repair
Funding
- Research Training Network Developing a stem cell based therapy to replace nephrons lost through reflux nephropathy
- European Community as part of the Framework program 6 [FP6 036097-2]
- European Community [223007]
- STAR-TREK project
Ask authors/readers for more resources
Mesenchymal stem cells (MSCs) of bone marrow origin appear to be an attractive candidate for cell-based therapies. However, the major barrier to the effective implementation of MSC-based therapies is the lack of specific homing of exogenously infused cells and overall the inability to drive them to the diseased or damaged tissue. In order to circumvent these limitations, we developed a preconditioning strategy to optimize MSC migration efficiency and potentiate their beneficial effect at the site of injury. Initially, we screened different molecules by using an in vitro injury-migration setting, and subsequently, we evaluated the effectiveness of the different strategies in mice with acute kidney injury (AKI). Our results showed that preconditioning of MSCs with IGF-1 before infusion improved cell migration capacity and restored normal renal function after AKI. The present study demonstrates that promoting migration of MSCs could increase their therapeutic potential and indicates a new therapeutic paradigm for organ repair.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available